PureTech Health plc (NASDAQ:PRTC - Get Free Report) shares fell 5.9% on Friday . The company traded as low as $27.91 and last traded at $27.96. 4,573 shares traded hands during trading, an increase of 2% from the average session volume of 4,481 shares. The stock had previously closed at $29.70.
PureTech Health Stock Performance
The business's 50 day moving average is $25.86 and its two-hundred day moving average is $23.42.
Institutional Trading of PureTech Health
An institutional investor recently raised its position in PureTech Health stock. Jane Street Group LLC boosted its stake in PureTech Health plc (NASDAQ:PRTC - Free Report) by 15.5% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,632 shares of the company's stock after purchasing an additional 1,289 shares during the quarter. Jane Street Group LLC's holdings in PureTech Health were worth $263,000 as of its most recent SEC filing. Institutional investors own 0.04% of the company's stock.
PureTech Health Company Profile
(
Get Free Report)
PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies.
Recommended Stories
Before you consider PureTech Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.
While PureTech Health currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
